Search research articles
Contact Us
Filters
Showing results (1-10 of 37) with videos related to
Page
of 4
Sort By:
Current Pharmaceutical Design
|
August 13, 2002
SERMs: evolutionary chemistry, revolutionary biology
Chris P Miller
Chirality
|
January 18, 2008
A consideration of the patentability of enantiomers in the pharmaceutical industry in the United States
Chris P Miller, John W Ullrich
Anticancer Research
|
April 22, 2011
Quantitative comparison of erythropoietin receptor levels in the epithelial versus endothelial fractions of primary breast tumors
Chris P Miller, Nicole Urban, C Anthony Blau
Bioorganic & Medicinal Chemistry Letters
|
June 26, 2003
Constrained phytoestrogens and analogues as ERbeta selective ligands
Chris P Miller, Michael D Collini, Heather A Harris
Blood
|
January 25, 2002
Erythropoietin receptor-dependent erythroid colony-forming unit development: capacities of Y343 and phosphotyrosine-null receptor forms
Chris P Miller, Destin W Heilman, Don M Wojchowski
Translational Oncology
|
June 22, 2010
Limitations of a murine transgenic breast cancer model for studies of erythropoietin-induced tumor progression
Chris P Miller, Karine Valliant-Saunders, Carl Anthony Blau
Neoplasia (New York, N.Y.)
|
May 11, 2018
A 3D Human Renal Cell Carcinoma-on-a-Chip for the Study of Tumor Angiogenesis
Chris P Miller, Connor Tsuchida, Ying Zheng, et al.
Human Vaccines & Immunotherapeutics
|
March 5, 2021
Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma
Yuexin Xu, Chris P Miller, Edus H Warren, et al.
Experimental Hematology
|
June 26, 2007
MicroRNA expression dynamics during murine and human erythroid differentiation
Mei Zhan, Chris P Miller, Thalia Papayannopoulou, et al.
Frontiers in Cell and Developmental Biology
|
May 10, 2024
Signaling crosstalk between tumor endothelial cells and immune cells in the microenvironment of solid tumors
Yuexin Xu, Chris P Miller, Scott S Tykodi, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 37) with videos related to
Sort By:
Page
of 4
Current Pharmaceutical Design
|
August 13, 2002
SERMs: evolutionary chemistry, revolutionary biology
Chris P Miller
Chirality
|
January 18, 2008
A consideration of the patentability of enantiomers in the pharmaceutical industry in the United States
Chris P Miller, John W Ullrich
Anticancer Research
|
April 22, 2011
Quantitative comparison of erythropoietin receptor levels in the epithelial versus endothelial fractions of primary breast tumors
Chris P Miller, Nicole Urban, C Anthony Blau
Bioorganic & Medicinal Chemistry Letters
|
June 26, 2003
Constrained phytoestrogens and analogues as ERbeta selective ligands
Chris P Miller, Michael D Collini, Heather A Harris
Blood
|
January 25, 2002
Erythropoietin receptor-dependent erythroid colony-forming unit development: capacities of Y343 and phosphotyrosine-null receptor forms
Chris P Miller, Destin W Heilman, Don M Wojchowski
Translational Oncology
|
June 22, 2010
Limitations of a murine transgenic breast cancer model for studies of erythropoietin-induced tumor progression
Chris P Miller, Karine Valliant-Saunders, Carl Anthony Blau
Neoplasia (New York, N.Y.)
|
May 11, 2018
A 3D Human Renal Cell Carcinoma-on-a-Chip for the Study of Tumor Angiogenesis
Chris P Miller, Connor Tsuchida, Ying Zheng, et al.
Human Vaccines & Immunotherapeutics
|
March 5, 2021
Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma
Yuexin Xu, Chris P Miller, Edus H Warren, et al.
Experimental Hematology
|
June 26, 2007
MicroRNA expression dynamics during murine and human erythroid differentiation
Mei Zhan, Chris P Miller, Thalia Papayannopoulou, et al.
Frontiers in Cell and Developmental Biology
|
May 10, 2024
Signaling crosstalk between tumor endothelial cells and immune cells in the microenvironment of solid tumors
Yuexin Xu, Chris P Miller, Scott S Tykodi, et al.
Page
of 4